Lucentis’ share of US new Rx’s slipped from 50% to the low 40’s in the most recent quarter as Lucentis is losing out to off-label Avastin among retinal specialists. (Source: Today’s DNA CC)
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”